VOR Stock Forecast: Vor Biopharma, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Vor Biopharma, Inc. hold a median 12-month price target of $40 — +108.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 23 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Vor Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (84): Sales and profits are climbing, and climbing faster than before.
Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VOR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VOR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +108.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | William Blair | Initiates | Outperform | — |
| 12 Aug 2026 | Wedbush | Maintains | Neutral | $18 → $27 |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $31 |
| 14 May 2026 | Wedbush | Maintains | Neutral | $15 → $18 |
| 15 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Mar 2026 | Wedbush | Maintains | Neutral | — |
| 30 Mar 2026 | Jefferies | Initiates | Buy | — |
| 19 Mar 2026 | Wells Fargo | Initiates | Overweight | — |
| 9 Jan 2026 | Citigroup | Initiates | Buy | — |
| 19 Dec 2025 | JP Morgan | Maintains | Overweight | — |
| 17 Dec 2025 | TD Cowen | Initiates | Buy | — |
| 9 Dec 2025 | JP Morgan | Initiates | Overweight | — |
| 25 Nov 2025 | Wedbush | Assumes | Neutral | $9.00 |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Oct 2025 | Baird | Upgrade | Outperform | — |
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 June 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 27 June 2025 | Baird | Maintains | Neutral | — |
| 26 June 2025 | Wedbush | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VOR.
This page is one stock. Monday covers all of them.
VOR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VOR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Vor Biopharma, Inc. returned +179.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VOR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.1×
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 96% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −27.5%
- Dividend yield
- —
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vor Biopharma, Inc. has a market value of $1.2B and an enterprise value of $700.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: $627.8M.
Free cash flow in the twelve months to 30 June 2026: −$140.8M.
Trailing P/E: 0.1×.
Vor Biopharma, Inc. employs 76 people.
Data provided by Twelve Data
VOR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VOR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Vor Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VOR
What is the VOR stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Vor Biopharma, Inc. have a median 12-month price target of $40, with estimates ranging from $27 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VOR stock a buy right now?
Of the 10 analysts covering Vor Biopharma, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vor Biopharma, Inc. 23 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VOR?
As at 21 Nov 2026, Vor Biopharma, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).
Will VOR stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +108.8% from the last close, and Ticker Nerd's factor model ranks Vor Biopharma, Inc. 23 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VOR stock forecast for 2030?
No analyst covering Vor Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $50 over the next 12 months.
How has VOR stock performed over the past year?
Vor Biopharma, Inc. returned +179.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Vor Biopharma, Inc. do?
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions.
About Vor Biopharma, Inc.
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions. The company’s current development and commercialization efforts center on autoimmune indications such as generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s disease, and IgA nephropathy. Vor Biopharma works on advancing this therapy through clinical development and broader market access, positioning its platform within the specialized immunology and biopharmaceutical segments. Headquartered in Cambridge, Massachusetts, Vor Biopharma plays a role in the market by addressing serious chronic diseases with targeted biologic treatment approaches.
CEO Dr. Jean-Paul Kress M.D. · 76 employees · United States · https://www.vorbio.com